We are live on ! Find out more
STLN

Starling Oncology Institute, Inc. Common Stock
STLN

31 hedge funds and large institutions have $4.61M invested in Starling Oncology Institute, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

7.8% less ownership

Funds ownership: 27.27% → 19.47% (-7.8%)

9% less funds holding

Funds holding: 34 → 31 (-3)

34% less capital invested

Capital invested by funds: $6.98M → $4.61M (-$2.37M)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
31
Holders Change
-3
Holders Change %
-8.82%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
3
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FL
FreeGulliver LLC
Louisiana
+$107K
2
TAS
TIFF Advisory Services
Pennsylvania
+$89.8K
3
VF
Virtu Financial
New York
+$34.2K
4
Jane Street
Jane Street
New York
+$28.5K
5
UBS Group
UBS Group
Switzerland
+$16.1K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.55M
2
KLP
Kent Lake PR
Puerto Rico
-$654K
3
BFM
Boston Financial Management
Massachusetts
-$253K
4
Citadel Advisors
Citadel Advisors
Florida
-$29.9K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$1.04M – – –
TAS
2
TIFF Advisory Services
Pennsylvania
$921K +$89.8K +346,256 +13%
CI
3
Cincinnati Insurance
Ohio
$629K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$542K -$7.54K -29,068 -2%
Balyasny Asset Management
5
Balyasny Asset Management
Illinois
$533K – – –
FL
6
FreeGulliver LLC
Louisiana
$186K +$107K +412,578 +219%
QFA
7
Quattro Financial Advisors
Texas
$113K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$107K -$8.46K -32,634 -9%
FCM
9
FourWorld Capital Management
New York
$79.4K – – –
BlackRock
10
BlackRock
New York
$78.4K +$169 +651 +0.3%
Renaissance Technologies
11
Renaissance Technologies
New York
$56.2K +$3.11K +12,000 +7%
VF
12
Virtu Financial
New York
$41K +$34.2K +131,759 New
Jane Street
13
Jane Street
New York
$39.4K +$28.5K +109,769 +614%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$38.7K – – –
State Street
15
State Street
Massachusetts
$31.3K – – –
SCM
16
Saba Capital Management
New York
$29.1K – – –
HighTower Advisors
17
HighTower Advisors
Illinois
$25.1K – – –
LF
18
Lee Financial
Texas
$25.1K – – –
FCG
19
Fielder Capital Group
Tennessee
$21.7K – – –
Northern Trust
20
Northern Trust
Illinois
$20.1K – – –
UBS Group
21
UBS Group
Switzerland
$19.1K +$16.1K +61,961 New
XT
22
XTX Topco
Cayman Islands
$11.5K +$3.15K +12,141 +48%
Morgan Stanley
23
Morgan Stanley
New York
$9.39K – – –
SRL
24
Scientech Research LLC
New Jersey
$6.55K +$5.5K +21,198 New
TRCT
25
Tower Research Capital (TRC)
New York
$4.18K +$1.23K +4,741 +54%
1
2

STLN Hedge Fund Activity: Q4 2024 in Review

31 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q4 2024, worth a combined $4.61M — down 34% from $6.98M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of STLN and 5 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 9 added.

The largest buyer was FreeGulliver LLC, adding an estimated $107K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.55M sold.

  • 31 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q4 2024, down from 34 in Q3 2024.
  • Funds reported $4.61M of Starling Oncology Institute, Inc. Common Stock stock for Q4 2024, down 34% quarter-over-quarter.
  • 5 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q4 2024 and 8 closed out, a net change of -3 holders.
  • The largest Starling Oncology Institute, Inc. Common Stock buyer in Q4 2024 was FreeGulliver LLC, an estimated $107K added.
  • The largest Starling Oncology Institute, Inc. Common Stock seller in Q4 2024 was Fidelity Investments, an estimated $1.55M sold.

Based on aggregated 13F filings for Q4 2024.